Intravenous Immunoglobulin Market Report 2026

The intravenous immunoglobulin market size has grown strongly in recent years. It will grow from $15.57 billion in 2025 to $16.86 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising prevalence of primary immunodeficiency diseases, advancements in immunoglobulin purification techniques, increased hospital-based ivig administration, growing awareness about autoimmune disorders, expansion of ivig production facilities.

The intravenous immunoglobulin market size is expected to see strong growth in the next few years. It will grow to $23.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for home-based ivig therapy, development of biosimilar ivig products, integration of automated infusion technologies, expanding applications in neurological disorders, growth in emerging markets for immunoglobulin therapies. Major trends in the forecast period include personalized immunoglobulin therapy, home-based ivig administration, biosimilar development and adoption, enhanced purification and safety protocols, automated infusion systems.

The growing geriatric population is expected to drive the expansion of the intravenous immunoglobulin (IVIG) market. The geriatric population refers to individuals aged 65 and older. As people age, their immune system often becomes less effective, leading to a lack of antibodies. This creates a need for immunoglobulins to provide the necessary antibodies, boosting demand for intravenous immunoglobulins. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, projected that the number of Americans aged 65 and older will grow from 58 million in 2022 to 82 million by 2050, a 47% increase. During the same period, this age group's share of the total population is expected to rise from 17% to 23%. Consequently, the increasing geriatric population will contribute to the growth of the intravenous immunoglobulin market.

Major companies in the intravenous immunoglobulin (IVIG) market are focusing on introducing innovative products, such as plasma-derived medicines, and seeking approval from federal agencies like the U.S. FDA to gain a competitive advantage. The introduction of FDA-approved IVIG solutions signals the approval of new therapies for treating specific medical conditions. For example, in June 2024, Biotest AG, a Germany-based supplier of plasma proteins and products, announced the FDA approval of Yimmugo for treating primary immunodeficiencies (PIDs). Yimmugo, an intravenous immunoglobulin, contains pooled human plasma-derived immunoglobulin G (IgG), which is essential for immune support in patients with PIDs. The approval reflects the growing demand for plasma-derived therapies, underscoring the need for effective treatments for patients with weakened immune systems. Yimmugo expands Grifols' existing portfolio of intravenous and subcutaneous immunoglobulins, providing additional options for patients dependent on these vital medicines.

In February 2024, Ridgemont Equity Partners, a US-based equity investment firm, acquired American Outcomes Management for an undisclosed amount. This acquisition aligns with Ridgemont's strategic focus on the growing specialty infusion market, which is driven by an aging population with chronic conditions and an increasing demand for at-home treatment options. American Outcomes Management is a US-based provider of intravenous immunoglobulin (IVIG) infusion therapy.

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

North America was the largest region in the intravenous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous immunoglobulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the intravenous immunoglobulin market by increasing costs of imported raw immunoglobulins and infusion equipment, disrupting supply chains, and affecting production timelines. Hospitals and clinics in regions like North America and Europe, which rely on imported IVIG, are most impacted. Some local manufacturers are leveraging tariffs to expand domestic production and reduce dependency on imports, creating opportunities for cost optimization and innovation in biosimilar and automated infusion solutions.

The intravenous immunoglobulin market research report is one of a series of new reports that provides intravenous immunoglobulin market statistics, including intravenous immunoglobulin industry global market size, regional shares, competitors with a intravenous immunoglobulin market share, detailed intravenous immunoglobulin market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous immunoglobulin industry. This intravenous immunoglobulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Intravenous immunoglobulin (IVIG) is a therapy used to treat individuals with immunodeficiency. It is administered through an intravenous infusion and consists of immunoglobulins collected from healthy individuals and purified to remove any blood-borne infections or impurities.

The main types of intravenous immunoglobulin include Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin A (IgA), Immunoglobulin E (IgE), and Immunoglobulin D (IgD). Immunoglobulin G (IgG) is the most common type found in blood and other body fluids and plays a key role in defending the body against bacterial and viral infections. IgG is used to enhance the body’s natural defense mechanisms. IVIG products are distributed through hospital pharmacies, retail pharmacies, and other outlets, and are used in the treatment of conditions such as hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, and others. The primary end-users of IVIG include hospitals, clinics, and home care providers.

The intravenous immunoglobulin market consists of sales of intravenous immunoglobulin used for treating people with antibody deficiencies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.